Department of Prosthodontics, School and Hospital of Stomatology, Peking University, Beijing, China.
PLoS One. 2013;8(2):e56002. doi: 10.1371/journal.pone.0056002. Epub 2013 Feb 11.
Human adipose-derived stromal cells (hASCs) are a promising cell source for bone tissue engineering. However, before the clinical application of hASCs for the treatment of bone defects, key questions require answers, including whether pre-osteoinduction (OI) and flow cytometric cell purification are indispensible steps for in vivo bone formation by hASCs. In this study, hASCs were purified by flow cytometric cell sorting (FCCS). The osteogenic capabilities of hASCs and purified hASCs with or without pre-osteoinduction were examined through in vitro and in vivo experiments. We found that pre-OI enhanced the in vitro osteogenic capacity of hASCs. However, 8 weeks after in vivo implantation, there were no significant differences between hASCs and hASCs that had undergone OI (hASCs+OI) or between purified hASCs and purified hASCs+OI (P>0.05). Interestingly, we also found that purified hASCs had an osteogenic potential similar to that of unpurified hASCs in vitro and in vivo. These results suggest that FCCS and in vitro pre-OI are not requirements for in vivo bone formation by hASCs.
人脂肪来源的基质细胞（hASCs）是骨组织工程有前途的细胞来源。然而，在 hASCs 用于治疗骨缺损的临床应用之前，需要回答一些关键问题，包括 hASCs 体内成骨是否必须经过预成骨诱导（OI）和流式细胞术细胞纯化这两个步骤。在本研究中，通过流式细胞术细胞分选（FCCS）对 hASCs 进行纯化。通过体外和体内实验研究了 hASCs 及未经预成骨诱导的和经预成骨诱导的 hASCs （hASCs+OI）和纯化的 hASCs 及经纯化和预成骨诱导的 hASCs（hASCs+OI+P）的成骨能力。我们发现预 OI 增强了 hASCs 的体外成骨能力。然而，在体内植入 8 周后，hASCs 和 hASCs+OI 之间、纯化的 hASCs 和 hASCs+OI+P 之间没有显著差异（P>0.05）。有趣的是，我们还发现，在体外和体内，纯化的 hASCs 具有与未纯化的 hASCs 相似的成骨潜力。这些结果表明，FCCS 和体外预 OI 不是 hASCs 体内成骨的必要条件。
